Trial Profile
Efficacy and Safety of 3 Doses of S201086/GLPG1972 Administered Orally Once Daily in Patients With Knee Osteoarthritis. A 52-week International, Multi-regional, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Aldumastat (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Acronyms ROCCELLA
- Sponsors Galapagos NV
- 01 Jul 2023 Results published in the Osteoarthritis and Cartilage
- 15 Oct 2020 Results published in Galapagos NV Media Release.
- 15 Oct 2020 According to a Galapagos NV media release, Additional analyses are being conducted to fully evaluate the results, which will be presented at upcoming medical conferences.